1. The Reliable Life Defense

2. Each vial contains: Each vial contains: Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume of 1 ml. Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume of 1 ml.

3. Filgrastim Filgrastim is a glycoprotein which acts on hematopoietic cells in bone marrow, stimulating their proliferation & differentiation to neutrophils. Filgrastim Filgrastim accelerates improvement of neutrophils count & their functional activation (enhanced phagocytic ability) Filgrastim Filgrastim is a glycoprotein which acts on hematopoietic cells in bone marrow, stimulating their proliferation & differentiation to neutrophils. Filgrastim Filgrastim accelerates improvement of neutrophils count & their functional activation (enhanced phagocytic ability)

4. To reduce the incidence, severity & duration of neutropenia associated with chemotherapy (Interferon) Cancer patients receiving myelosuppressive chemotherapy Patients with acute myeloid leukemia receiving induction Chemotherapy Patients with severe chronic neutropenia

5. Cancer patients undergoing peripheral Blood Progenitor Cell Collection and Therapy Cancer patients receiving bone marrow transplant Patients with acute myeloid leukemia receiving induction Chemotherapy Patients with severe chronic neutropenia

6. Filgrastim dose: 4 to 8 mcg/kg for up to 14 consecutive days following each cycle of chemotherapy Duhrsen U Villeval JL Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081. Cancer Patients Receiving Myelo- suppressive Chemotherapy

7. Dosage & Administration is individualized according to patients clinical course & average neutrophil count Filgrastim Filgrastim should be given once daily by I.V. or S.C. injection (after 24 – 48 hours of administration of chemotherapy or radiotherapy)

8. Cancer patients receiving myelosuppressive chemotherapy: Cancer patients receiving myelosuppressive chemotherapy: 5 µg/kg body weight /day as a single daily dose by S.C. injection or I.V. infusion over 15 – 30 minutes

9. Patients with severe chronic neutropenia: Patients with severe chronic neutropenia: Initial dose Congenital: 6µg/kg body weight twice daily by S.C. injection Idiopathic: 5µg/kg body weight /day as a single S.C. injection

10. Cancer patients receiving bone marrow transplant: Cancer patients receiving bone marrow transplant: 10 µg/kg body weight /day as I.V. infusion for 4 – 24 hours

11. Cancer patients undergoing peripheral Blood Progenitor Cell Collection and Therapy: Cancer patients undergoing peripheral Blood Progenitor Cell Collection and Therapy: 10 µg/kg body weight /day either as a bolus or a continuous infusion at least 4 days before the first procedure for 6 – 7 days, on day 5,6,7. Dose modification in case of reaching WBCs count exceeding 100,000 / mm 3

12. Filgrastim Filgrastim is kept in refrigerator at 2 – 8 o C Filgrastim Filgrastim can be kept at room temp. for a maximum of 24 hours Filgrastim Filgrastim vial should not be shacked Filgrastim Filgrastim vial should not be reused, the unused portion must be discarded

13. 1 vial (1 ml) … 350 L E. 1 vial (1 ml) … 350 L E.

14. The Reliable Life Defense